PharmaCyte Biotech surges 82.21% intraday on FDA optimism and Femasys monetization boosting cash reserves.

PharmaCyte Biotech surged 82.21% intraday, driven by FDA-related optimism and the monetization of its stake in Femasys Inc., which boosted cash reserves to $20 million. Recent news highlighted the company’s strategic capital deployment, with the cash infusion strengthening liquidity and validating its market position. The stock’s rally aligns with reports of promising cancer therapy advancements and regulatory milestones, which fueled speculative interest amid the biotech sector’s volatile momentum.